Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Results save search
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CORT | News | $23.0 3.14% 3.04% 1.9M
|
Health Technology
|
| O: -6.86%
H: 6.89%
C: 4.6%
positive trial results
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.99 -0.26% -0.26% 1.4M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $128.64 2.7% -1.0% 3.5M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $12.95 0.47% 0.39% 820K
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
CTSO | $0.879 8.52% 8.27% 110K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
association presentation for meeting trial results
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
ICCM | $1.22 0.82% 67K
|
Manufacturing
| Email alert
Add to watchlist
free breast cancer medical trial results
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
MRNS | $1.44 -2.37% -1.37% 2.6M
|
Health Technology
|
| O: -75.4%
H: 5.41%
C: -29.73%
first update pharmaceuticals trial financial results
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8478 -3.66% -5.9% 86K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $13.01 1.01% -0.62% 8.1M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Published: 2024-04-11 (Crawled : 19:00) - globenewswire.com
ENLV | News | $1.32 3.94% 3.79% 1.3K
|
Health Technology
|
| O: 3.28%
H: 2.12%
C: -16.4%
topline trial results
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
ENLV | News | $1.32 3.94% 3.79% 1.3K
|
Health Technology
|
| O: -44.19%
H: 1.36%
C: -17.19%
topline trial results
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $8.0 1.78% 1.75% 290K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $11.97 0.17% 0.25% 310K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $6.42 -0.16% 1.2M
|
Health Technology
|
| O: 3.27%
H: 0.13%
C: -4.17%
association presentation cancer cell research meeting skin trial results
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.94 8.99% 7.29% 170
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.639 5.43% 4.55% 150
|
Health Care and Social Assistan...
|
| O: 1.34%
H: 0.0%
C: -4.21%
bt-600 positive trial therapeutics results platform
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Published: 2024-04-02 (Crawled : 23:00) - globenewswire.com
MNOV | $1.33 -0.75% -3.73% 9.4K
|
Health Technology
|
| O: 2.01%
H: 4.61%
C: 0.0%
mn-166 presentation meeting trial results glioblastoma
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
SGHT | $5.64 5.03% 4.79% 130K
|
|
| O: 6.8%
H: 2.07%
C: -9.98%
sciences meeting trial results
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
VIRX | $0.8478 -3.66% -5.9% 86K
|
Manufacturing
|
| O: 0.96%
H: 8.57%
C: 5.71%
congress topline trial therapeutics results
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
HLTH | $0.15 6.38% 7.84% 21K
|
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.